Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva Dombi

Showing results (31-40 of 100) with videos related to

Pageof 10
Sort By:
JCI Insight|February 8, 2019
Cxcr3-expressing leukocytes are necessary for neurofibroma formation in miceJonathan S Fletcher, Jianqiang Wu, Walter J Jessen, et al.
Journal of Neurosurgery|October 27, 2019
Safe marginal resection of atypical neurofibromas in neurofibromatosis type 1Charlie N Nelson, Eva Dombi, Jared S Rosenblum, et al.
Pediatric Blood & Cancer|April 25, 2015
Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of Neurofibromatosis type 1Edwin Jousma, Tilat A Rizvi, Jianqiang Wu, et al.
Endocrine-Related Cancer|October 24, 2012
Bone mineral density in children and young adults with neurofibromatosis type 1Maya B Lodish, Urania Dagalakis, Ninet Sinaii, et al.
American Journal of Ophthalmology|March 5, 2013
Visual outcomes in children with neurofibromatosis type 1 and orbitotemporal plexiform neurofibromasRobert A Avery, Eva Dombi, Kelly A Hutcheson, et al.
Life Science Alliance|September 24, 2025
Daytime SHP2 inhibitor dosing, when immune cell numbers are elevated, shrinks neurofibromasNiousha Ahmari, Kwangmin Choi, Jianqiang Wu, et al.
Cancer Research|August 21, 2020
<i>Cdkn2a</i> Loss in a Model of Neurofibroma Demonstrates Stepwise Tumor Progression to Atypical Neurofibroma and MPNSTKatherine E Chaney, Melissa R Perrino, Leah J Kershner, et al.
Pediatric Blood & Cancer|May 23, 2014
Sirolimus for non-progressive NF1-associated plexiform neurofibromas: an NF clinical trials consortium phase II studyBrian Weiss, Brigitte C Widemann, Pamela Wolters, et al.
Oncogene|December 9, 2020
MicroRNA-155 contributes to plexiform neurofibroma growth downstream of MEKYoujin Na, Ashley Hall, Kwangmin Choi, et al.
Pediatric Neurology|May 19, 2007
Phase I trial of pirfenidone in children with neurofibromatosis 1 and plexiform neurofibromasDusica Babovic-Vuksanovic, Brigitte C Widemann, Eva Dombi, et al.
Pageof 10

Showing results (31-40 of 100) with videos related to

Sort By:
Pageof 10
JCI Insight|February 8, 2019
Cxcr3-expressing leukocytes are necessary for neurofibroma formation in miceJonathan S Fletcher, Jianqiang Wu, Walter J Jessen, et al.
Journal of Neurosurgery|October 27, 2019
Safe marginal resection of atypical neurofibromas in neurofibromatosis type 1Charlie N Nelson, Eva Dombi, Jared S Rosenblum, et al.
Pediatric Blood & Cancer|April 25, 2015
Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of Neurofibromatosis type 1Edwin Jousma, Tilat A Rizvi, Jianqiang Wu, et al.
Endocrine-Related Cancer|October 24, 2012
Bone mineral density in children and young adults with neurofibromatosis type 1Maya B Lodish, Urania Dagalakis, Ninet Sinaii, et al.
American Journal of Ophthalmology|March 5, 2013
Visual outcomes in children with neurofibromatosis type 1 and orbitotemporal plexiform neurofibromasRobert A Avery, Eva Dombi, Kelly A Hutcheson, et al.
Life Science Alliance|September 24, 2025
Daytime SHP2 inhibitor dosing, when immune cell numbers are elevated, shrinks neurofibromasNiousha Ahmari, Kwangmin Choi, Jianqiang Wu, et al.
Cancer Research|August 21, 2020
<i>Cdkn2a</i> Loss in a Model of Neurofibroma Demonstrates Stepwise Tumor Progression to Atypical Neurofibroma and MPNSTKatherine E Chaney, Melissa R Perrino, Leah J Kershner, et al.
Pediatric Blood & Cancer|May 23, 2014
Sirolimus for non-progressive NF1-associated plexiform neurofibromas: an NF clinical trials consortium phase II studyBrian Weiss, Brigitte C Widemann, Pamela Wolters, et al.
Oncogene|December 9, 2020
MicroRNA-155 contributes to plexiform neurofibroma growth downstream of MEKYoujin Na, Ashley Hall, Kwangmin Choi, et al.
Pediatric Neurology|May 19, 2007
Phase I trial of pirfenidone in children with neurofibromatosis 1 and plexiform neurofibromasDusica Babovic-Vuksanovic, Brigitte C Widemann, Eva Dombi, et al.
Pageof 10